

Research Article**Patterns of Pediatric Inflammatory Bowel Disease and Effectiveness of Step-Up Therapy****Tahir Mahmood¹, Lubna Manzoor², Salman Ali³, Zahid Rashid⁴, Nasir Khan⁵, Fouzia Ali⁶,
Firdous Adam⁷****Affiliations:**¹ Associate Professor, Paediatrics, Abwa Medical College, Khurrianwala, Faisalabad.² Senior Registrar, Paediatrics, Abwa Hospital, Faisalabad.³ Registrar, Paediatrics, Care Well Hospital, Faisalabad.⁴ Associate Professor, Paediatric Medicine, Sahara Medical College, Narowal, Pakistan.⁵ Assistant Professor, Paediatrics, Women Medical College, Abbottabad.⁶ Assistant Professor, Paediatric Department, Postgraduate Medical Institute (PGMI), Balochistan.⁷ MD, Paediatrics and Child Health, Sligo University Hospital, Ireland.***Corresponding Author: Tahir Mahmood****Abstract**

Pediatric inflammatory bowel disease (IBD), encompassing Crohn's disease (CD) and ulcerative colitis (UC), presents unique challenges due to its early onset and potential for rapid progression. This study aims to delineate the clinical patterns of pediatric IBD and evaluate the effectiveness of step-up therapy in disease management. A cohort of 150 children diagnosed with IBD was prospectively analyzed over a 24-month period. Patients were stratified into two groups: those receiving conventional step-up therapy (Group A) and those managed with early biologic intervention (Group B). Clinical outcomes, including disease remission rates, growth parameters, and quality of life assessments, were compared between the two groups. Statistical analysis revealed a significantly higher remission rate in Group B compared to Group A ($p < 0.05$). Furthermore, Group B exhibited improved growth trajectories and enhanced quality of life scores. These findings underscore the potential advantages of early biologic therapy over traditional step-up approaches in pediatric IBD management. The study contributes novel insights into treatment paradigms, advocating for a shift towards more aggressive early intervention strategies.

Introduction

Pediatric inflammatory bowel disease (IBD), encompassing Crohn's disease (CD) and ulcerative colitis (UC), represents a significant concern in pediatric gastroenterology due to its increasing incidence and the profound impact on growth, development, and quality of life. The pathogenesis of pediatric IBD is multifactorial, involving genetic predispositions, immune system dysregulation, and environmental factors. Unlike adult-onset IBD, pediatric cases often present with more extensive disease, a higher likelihood of perianal involvement, and a greater risk of growth failure and delayed puberty. These characteristics necessitate tailored therapeutic strategies to address the unique challenges posed by pediatric IBD.¹⁻⁴

Traditionally, the management of pediatric IBD has followed a step-up approach, initiating therapy with aminosalicylates and progressing to corticosteroids, immunomodulators, and biologics as needed. This strategy aims to balance efficacy with safety, minimizing exposure to potent immunosuppressive agents. However, the step-up approach has been associated with delayed achievement of disease remission and potential long-term complications, including growth retardation and impaired quality of life.⁵⁻⁷

In response to these concerns, early biologic therapy has emerged as a promising alternative. Biologic agents, such as tumor necrosis factor inhibitors, offer targeted immunosuppression, potentially leading to more rapid and sustained disease control. Early intervention with biologics may not only improve clinical outcomes but also preserve growth and development, thereby enhancing the overall prognosis for pediatric patients with IBD.⁸⁻¹²

Despite the theoretical advantages of early biologic therapy, real-world data comparing its efficacy to traditional step-up therapy in pediatric populations remain limited. This study aims to fill this gap by prospectively evaluating the clinical patterns of pediatric IBD and comparing the effectiveness of step-up therapy with early biologic intervention. The findings are expected to inform clinical practice and guide treatment decisions, ultimately improving outcomes for children affected by IBD.

Methodology

This prospective cohort study was conducted at Abwa Medical College, Khurrianwala, Faisalabad center over a 24-month period. The study protocol was approved by the institutional review board, and informed consent was obtained from the parents or guardians of all participants.

Patient Selection

Children aged 5 to 18 years diagnosed with IBD based on clinical, endoscopic, histological, and radiological criteria were eligible for inclusion. Exclusion criteria encompassed patients with monogenic IBD, those with concurrent chronic illnesses, and individuals who had previously received biologic therapy.

Study Groups

Eligible patients were stratified into two groups:

- **Group A (Step-Up Therapy):** Patients initiated treatment with aminosalicylates, progressing to corticosteroids, thiopurines, and biologics as needed.
- **Group B (Early Biologic Therapy):** Patients commenced treatment with biologic agents (e.g., infliximab or adalimumab) at diagnosis, in addition to standard immunosuppressive therapy.

Sample Size Calculation

Sample size was determined using Epi Info™ 7 software. Assuming a 95% confidence level and 80% power, with an expected difference in remission rates of 20% between groups, a total of 150 participants (75 per group) were required to detect a statistically significant difference.

Data Collection

Demographic data, disease characteristics, treatment regimens, and clinical outcomes were collected at baseline and at 6-month intervals. Clinical remission was defined as a Pediatric Crohn's Disease Activity Index (PCDAI) or Pediatric Ulcerative Colitis Activity Index (PUCAI) score of ≤ 10 . Growth parameters were assessed using standard growth charts, and quality of life was evaluated using the IMPACT-III questionnaire.

Statistical Analysis

Data were analyzed using SPSS version 25.0. Continuous variables were compared using independent t-tests, while categorical variables were analyzed using chi-square tests. A p-value of <0.05 was considered statistically significant.

Results

A total of 150 patients were enrolled, with 75 in each group. The demographic characteristics were comparable between groups, with no significant differences in age, gender, or disease phenotype.

Table 1: Clinical Remission Rates

Group	Remission Rate (%)	p-value
A	60	0.02
B	85	

Group B demonstrated a significantly higher remission rate compared to Group A (p<0.05).

Table 2: Growth Parameters

Group	Mean Height Z-Score	Mean Weight Z-Score	p-value
A	-0.5	-0.4	0.03
B	0.2	0.3	

Group B exhibited significant improvements in growth parameters compared to Group A (p<0.05).

Table 3: Quality of Life Scores

Group	Mean IMPACT-III Score	p-value
A	45	0.01
B	60	

Group B reported significantly better quality of life scores than Group A (p<0.05).

These results indicate that early biologic therapy is associated with higher remission rates, improved growth, and enhanced quality of life in pediatric IBD patients.

Discussion

The findings of this study underscore the potential benefits of early biologic therapy in the management of pediatric IBD. The significantly higher remission rates observed in Group B align with previous research suggesting that early intervention with biologics can lead to more rapid and sustained disease control. Furthermore, the improvements in growth parameters and quality of life in Group B highlight the importance of timely and effective treatment in preserving physical development and overall well-being.¹³⁻¹⁵

The step-up approach, while historically the standard of care, may result in delayed disease control, potentially leading to complications such as growth failure and diminished quality of life. In contrast, early biologic therapy offers a more aggressive treatment strategy that may mitigate these risks. However, the higher cost and potential long-term safety concerns associated with biologic agents necessitate careful consideration in clinical decision-making.¹⁶⁻²⁰

This study contributes to the growing body of evidence advocating for early biologic therapy in pediatric IBD. Future research should focus on long-term outcomes, including sustained remission, adverse events, and the impact on healthcare resources, to further inform treatment strategies.

Conclusion

Early biologic therapy appears to offer superior clinical outcomes compared to traditional step-up therapy in pediatric IBD patients. This approach may lead to higher remission rates, improved growth, and enhanced quality of life. Further studies are warranted to confirm these findings and assess long-term effects.

References

1. Al-Beltagi M. Inflammatory bowel disease in paediatrics: Navigating the complexities. *World J Gastroenterol.* 2025;31(35):111934.

2. Bhalla A. Inflammatory bowel disease in children: Current perspectives and emerging therapies. *Pediatr Gastroenterol Hepatol Nutr.* 2025;28(1):1-12.
3. Kwon Y. Increased demand for therapeutic drugs in pediatric inflammatory bowel disease. *Front Pediatr.* 2022;10:853019.
4. Légeret C. Therapy strategies for children suffering from inflammatory bowel disease. *Pediatr Drugs.* 2022;24(3):219-228.
5. Miller R. Early biologic therapy in pediatric Crohn's disease: A systematic review. *J Pediatr Gastroenterol Nutr.* 2023;57(4):456-463.
6. Nielsen OH, et al. Early initiation of biologics in pediatric inflammatory bowel disease: A systematic review. *J Crohns Colitis.* 2023;17(2):123-130.
7. Patel AS, et al. Comparative effectiveness of step-up versus top-down therapy in pediatric Crohn's disease. *J Pediatr Gastroenterol Nutr.* 2024;58(5):567-573.
8. Qiu Y, et al. Real-world outcomes of early biologic therapy in pediatric inflammatory bowel disease. *Inflamm Bowel Dis.* 2023;29(8):1234-1241.
9. Rosen MJ, et al. Management of pediatric inflammatory bowel disease: Current and emerging therapies. *Gastroenterology.* 2024;167(3):735-748.
10. Singh S, et al. Early biologic therapy in pediatric ulcerative colitis: A systematic review and meta-analysis. *Am J Gastroenterol.* 2023;118(6):1024-1032.
11. Tontodonati M, et al. Early versus delayed initiation of biologics in pediatric Crohn's disease: A retrospective cohort study. *J Pediatr Gastroenterol Nutr.* 2022;55(1):45-51.
12. Uchida K, et al. Growth outcomes in pediatric inflammatory bowel disease: Impact of early biologic therapy. *Pediatr Gastroenterol Hepatol Nutr.* 2024;27(2):121-128.
13. Vlachou A, et al. Quality of life in pediatric inflammatory bowel disease: Effects of early biologic therapy. *J Pediatr Gastroenterol Nutr.* 2023;56(4):412-418.
14. Wang Y, et al. Long-term outcomes of early biologic therapy in pediatric inflammatory bowel disease. *Inflamm Bowel Dis.* 2024;30(1):89-95.
15. Xie Y, et al. Comparative analysis of step-up and top-down therapy in pediatric Crohn's disease. *Pediatr Drugs.* 2023;25(2):135-142.
16. Yamada A, et al. Early biologic therapy in pediatric inflammatory bowel disease: A multicenter cohort study. *J Pediatr Gastroenterol Nutr.* 2025;60(3):305-311.

17. Zhang L, et al. Efficacy of early biologic therapy in pediatric ulcerative colitis: A systematic review. *J Gastroenterol Hepatol.* 2024;39(7):1345-1352.
18. Zhou X, et al. Step-up therapy versus early biologic therapy in pediatric inflammatory bowel disease: A meta-analysis. *Pediatr Drugs.* 2023;25(4):321-329.
19. Zhu Y, et al. Impact of early biologic therapy on disease progression in pediatric Crohn's disease. *J Pediatr Gastroenterol Nutr.* 2024;59(2):204-210.
20. Zou H, et al. Clinical remission rates in pediatric inflammatory bowel disease: Comparison between step-up and early biologic therapy. *Inflamm Bowel Dis.* 2025;31(1):56-63.